Frequencies of T cells (a, CD3+), B cells (b, CD19+), monocytes (c, CD14+), NK cells (d, CD3−, CD19−, CD16+) and dendritic cells (e, CD3-CD19-CD16-CD14-HLADR+) in PBMCs of patients receiving UCB under conventional immunosuppressive treatment developing no GVHD (non-nTreg no GVHD, n=10), patients receiving UCB under conventional immunosuppressive treatment developing GVHD (non-nTreg with GVHD, n=9) or additional nTreg transfer with (nTreg with GVHD, n=6) or without development of GVHD (nTreg no GVHD, n=6) at 6 months post-transplant, and of healthy controls (n=10) were determined as described in material and methods. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001